Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 2
2005 3
2006 5
2007 4
2008 3
2009 6
2010 6
2011 12
2012 18
2013 14
2014 10
2015 25
2016 28
2017 22
2018 30
2019 39
2020 47
2021 52
2022 59
2023 51
2024 26

Text availability

Article attribute

Article type

Publication date

Search Results

410 results

Results by year

Filters applied: . Clear all
Page 1
Genomic Landscape of Circulating Tumor DNA in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Treated With Abemaciclib: Data From the SCRUM-Japan Cancer Genome Screening Project.
Hattori M, Serelli-Lee V, Naito Y, Yamanaka T, Yasojima H, Nakamura R, Fujisawa T, Imai M, Nakamura Y, Bando H, Kawaguchi T, Yoshino T, Iwata H. Hattori M, et al. Among authors: yoshino t. JCO Precis Oncol. 2024 Apr;8:e2300647. doi: 10.1200/PO.23.00647. JCO Precis Oncol. 2024. PMID: 38635933
Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.
Kawamoto Y, Morizane C, Komatsu Y, Kondo S, Ueno M, Kobayashi S, Furukawa M, Lee L, Satoh T, Sakai D, Ikeda M, Imaoka H, Miura A, Hatanaka Y, Yokota I, Nakamura Y, Yoshino T. Kawamoto Y, et al. Among authors: yoshino t. Future Oncol. 2024 Apr 17. doi: 10.2217/fon-2023-0348. Online ahead of print. Future Oncol. 2024. PMID: 38629456 Free article. Review.
Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program.
Kotani D, Takashima A, Kato T, Satoh T, Masuishi T, Komatsu Y, Shiozawa M, Esaki T, Izawa N, Takeuchi S, Bando H, Iwasa S, Hasegawa H, Yamaguchi T, Taniguchi H, Ushida Y, Oizaki T, Inoue C, Yoshino T. Kotani D, et al. Among authors: yoshino t. Clin Colorectal Cancer. 2024 Mar 9:S1533-0028(24)00022-7. doi: 10.1016/j.clcc.2024.02.002. Online ahead of print. Clin Colorectal Cancer. 2024. PMID: 38553360
Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.
Gallois C, Shi Q, Pederson LD, André T, Iveson TJ, Sobrero AF, Alberts S, de Gramont A, Meyerhardt JA, George T, Schmoll HE, Souglakos I, Harkin A, Labianca R, Sinicrope FA, Oki E, Shields AF, Boukovinas I, Kerr R, Lonardi S, Yothers G, Yoshino T, Goldberg RM, Taieb J, Papamichael D. Gallois C, et al. Among authors: yoshino t. J Clin Oncol. 2024 Mar 28:JCO2301326. doi: 10.1200/JCO.23.01326. Online ahead of print. J Clin Oncol. 2024. PMID: 38547438
Future direction of total neoadjuvant therapy for locally advanced rectal cancer.
Kagawa Y, Smith JJ, Fokas E, Watanabe J, Cercek A, Greten FR, Bando H, Shi Q, Garcia-Aguilar J, Romesser PB, Horvat N, Sanoff H, Hall W, Kato T, Rödel C, Dasari A, Yoshino T. Kagawa Y, et al. Among authors: yoshino t. Nat Rev Gastroenterol Hepatol. 2024 Mar 14. doi: 10.1038/s41575-024-00900-9. Online ahead of print. Nat Rev Gastroenterol Hepatol. 2024. PMID: 38485756 Review.
Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial.
Lenz HJ, Parikh A, Spigel DR, Cohn AL, Yoshino T, Kochenderfer M, Elez E, Shao SH, Deming D, Holdridge R, Larson T, Chen E, Mahipal A, Ucar A, Cullen D, Baskin-Bey E, Kang T, Hammell AB, Yao J, Tabernero J. Lenz HJ, et al. Among authors: yoshino t. J Immunother Cancer. 2024 Mar 13;12(3):e008409. doi: 10.1136/jitc-2023-008409. J Immunother Cancer. 2024. PMID: 38485190 Free PMC article. Clinical Trial.
410 results